A fluvoxamine-caffeine interaction study

被引:97
作者
Jeppesen, U [1 ]
Loft, S [1 ]
Poulsen, HE [1 ]
Brosen, K [1 ]
机构
[1] UNIV COPENHAGEN,DEPT PHARMACOL,COPENHAGEN,DENMARK
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
fluvoxamine; caffeine; CYP1A2; interaction;
D O I
10.1097/00008571-199606000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The selective serotonin reuptake inhibitor fluvoxamine is a very potent inhibitor of the liver enzyme CYP1A2, which is the major P450 catalysing the biotransformation of caffeine. Thus, a pharmacokinetic study was undertaken with the purpose of documenting a drug-drug interaction between fluvoxamine and caffeine. The study was carried out as a randomized, in vivo, cross-over study including eight healthy volunteers, In Period A of the study, each subject took 200 mg caffeine orally, and in Period B, the subjects took fluvoxamine 50 mg per day for 4 days and 100 mg per day for 8 days, On day 8 in Period B, the subjects again ingested 200 mg caffeine, After caffeine intake, blood and urine were sampled at regular intervals, Caffeine and its three primary demethylated metabolites, paraxanthine, theobromine and theophylline in plasma and the same four compounds plus 11 more metabolites ire urine were assayed by HPLC. During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min(-1) to 21 ml min(-1) and the half-life increased from 5 to 31 h. The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min(-1); the N1- and N7-demethylation clearances decreased from 21 to 9 ml min(-1) and from 14 to 6 ml min(-1) respectively. The results confirm that CYP1A2 is the main enzyme catalysing the biotransformation of caffeine, in particular the N3-demethylation and partly the N1- and N7-demethylation, The results indicate that intake of caffeine during fluvoxamine treatment may lead to caffeine intoxication. Finally, our study provides additional evidence that fluvoxamine can be used to probe CYP1A2 in drug metabolism.
引用
收藏
页码:213 / 222
页数:10
相关论文
共 33 条
  • [1] FLUVOXAMINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS
    BENFIELD, P
    WARD, A
    [J]. DRUGS, 1986, 32 (04) : 313 - 334
  • [2] BERTHOU F, 1991, DRUG METAB DISPOS, V19, P561
  • [3] COMPARATIVE PHARMACOKINETICS OF CAFFEINE IN YOUNG AND ELDERLY MEN
    BLANCHARD, J
    SAWERS, SJA
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1983, 11 (02): : 109 - 126
  • [4] FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2
    BROSEN, K
    SKJELBO, E
    RASMUSSEN, BB
    POULSEN, HE
    LOFT, S
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) : 1211 - 1214
  • [5] HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM)
    BUTLER, MA
    IWASAKI, M
    GUENGERICH, FP
    KADLUBAR, FF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) : 7696 - 7700
  • [6] DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES
    BUTLER, MA
    LANG, NP
    YOUNG, JF
    CAPORASO, NE
    VINEIS, P
    HAYES, RB
    TEITEL, CH
    MASSENGILL, JP
    LAWSEN, MF
    KADLUBAR, FF
    [J]. PHARMACOGENETICS, 1992, 2 (03): : 116 - 127
  • [7] CAMPBELL ME, 1987, DRUG METAB DISPOS, V15, P237
  • [8] A URINARY METABOLITE RATIO THAT REFLECTS SYSTEMIC CAFFEINE CLEARANCE
    CAMPBELL, ME
    SPIELBERG, SP
    KALOW, W
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) : 157 - 165
  • [9] CAFFEINE METABOLISM IN A HEALTHY SPANISH POPULATION - N-ACETYLATOR PHENOTYPE AND OXIDATION PATHWAYS
    CARRILLO, JA
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) : 293 - 304
  • [10] CHARNEY DS, 1985, ARCH GEN PSYCHIAT, V42, P233